Home › Companies › ZBIO

Zenas BioPharma

ZBIO Rare disease Lead: NDA Submitted 1 Biotech Distilled article ↓

Dermatology Immunology Neurology Protein Small Molecule

Most recent annual filing: 2026-03-16

Pipeline (11 active programs)

obexelimab

Protein Target: CD19, FcγRIIb

IgG4-Related Disease NDA Submitted subcutaneous Bristol Myers Squibb
Relapsing Multiple Sclerosis Phase 2 subcutaneous Bristol Myers Squibb
Systemic Lupus Erythematosus Phase 2 subcutaneous Bristol Myers Squibb

orelabrutinib

ZB020

Small Molecule Target: BTK

Primary Progressive Multiple Sclerosis Phase 3 oral InnoCare
Secondary Progressive Multiple Sclerosis Phase 3 oral InnoCare

ZB021

Small Molecule Target: IL-17AA, IL-17AF

Psoriasis Phase 1 oral

ZB022

Small Molecule Target: TYK2

Undisclosed indication Preclinical oral

ZB014

Protein Target: CD19, FcγRIIb

Undisclosed indication Preclinical

ZB002

Protein Target: TNFα

Undisclosed indication

ZB004

Protein Target: CTLA-4

Undisclosed indication

ZB001

VRDN-001

Protein Target: IGF-1R

Undisclosed indication Zai Lab

Discontinued (2)

obexelimab — Rheumatoid Arthritis · Company does not intend to develop obexelimab further in RA due to the competitive landscape
obexelimab — Warm Autoimmune Hemolytic Anemia · Determined not to progress to a registration-directed trial based on expected length and expense of a potential Phase 3 trial

Biotech Distilled coverage (1)

2026-06-10 Zenas BioPharma (ZBIO) — Scientific Deep Dive for Obexelimab, Orelabrutinib and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.